Treatment approaches that transdifferentiate activated CAFs into this quiescent phenotype include all-trans retinoic acid (ATRA), minnelide and the vitamin D receptor agonist calcipotriol, which facilitate resolution of liver and pancreatic fibrosis and enhance pancreatic cancer therapy [18,97]. This evidence concerns the gene VDR and pancreatic neoplasm.